Mumbai, Aug. 11 -- The product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, and is used in the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus. It is also indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal motility in adult patients.

According to IQVIA MAT (June 2025) data, Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual sales of $122 million in the U.S. market.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex ...